GreenWave, I noted this mate.....Immutep CEO, Mr Marc Voigt...

GreenWave, I noted this mate.....

Immutep CEO, Mr Marc Voigt commented “IMP761 is a first-in-class product candidate that has thepotential to address the underlying cause of most autoimmune diseases. As leaders in the LAG-3space, we are very excited to be moving forward with this innovative program and I believe Immutepis well positioned to translate the science and pre-clinical evidence we are seeing for IMP761 into arevolutionary therapeutic approach for autoimmune diseases.”

upon reading this I thought to myself how the f**k are we gonna run all these trials.....

Also I have noticed "business development" being used frequently of late by the

company.......I reckon there is something cooking in the background in regard

to the business side of things......

i wouldn't expect too much SP move from this, afterall it's an intention to proceed

to trial notice.....I'd say we will see the data that convinced them to take it further

at esmo(oct) or sitc(nov)...